DOT Drug Testing: On and After October 1, 2010 – Still a 5-Panel
The DOT testing at HHS-certified laboratories will continue to be a 5-panel drug test regimen, on and after October 1, 2010. The 5-panel regimen will remain:
- Marijuana (THC)
- Cocaine
- Amphetamines
- Opiates
- Phencyclidine (PCP)
Under Opiates, DOT testing has always included confirmatory testing, when appropriate, for Codeine, Morphine, and 6-AM (heroin). Under Amphetamines, DOT testing has always included confirmatory testing, when appropriate, for Amphetamine and Methamphetamine. To this Amphetamines group, we are adding initial testing for MDMA and confirmatory testing for MDMA, MDA, & MDEA.
Broken out, here’s what drug testing will look like effective October 1st, with the confirmatory testing in red being new. [NOTE: Laboratories have always conducted confirmatory testing for 6-AM, when appropriate.]
- Marijuana (THC)
- Cocaine
- Amphetamines
- Amphetamine
- Methampheamine
- MDMA
- MDA
- MDEA
- Opiates
- Codeine
- Morphine
- 6-AM (heroin)
- Phencyclidine (PCP)
What does this mean for collectors, laboratories, MROs, and employers on and after October 1st for DOT testing?
- Collectors will continue to check the 5-panel box in Step 1 of the CCF: That is, the box specified for “THC, COC, PCP, OPI, AMP.”
- Laboratories will continue to report to MROs the specific drugs / drug metabolites they confirm as positive; and laboratories will be adding MDMA, MDA, and MDEA confirmed positives, as appropriate.
- Laboratories will add – on their semi-annual reports to DOT and their semi-annual reports to employers – MDMA, MDA, and MDEA confirmed positive totals, as appropriate, under Amphetamines.
- MROs will continue to report to employers the specific drugs / drug metabolite they verify as positive; and MROs will be adding MDMA, MDA, and MDEA verified positives, as appropriate.
- Employers will continue to provide – on their annual MIS reports – the number of verified positive drug test results in each testing category (i.e., Marijuana, Cocaine, Amphetamines, Opiates, and PCP).
For additional clarification, please contact Mark Snider at 202 366 3784 or mark.snider@dot.gov